Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Peking University Cancer Hospital & Institute
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
66High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07567326CT.gov Adebrelimab or Retlirafusp Alfa Plus Recaticimab and Chemotherapy for Resectable NSCLC | — | Not Yet Recruiting | — | — | — |
NCT07464327CT.gov A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations | — | Not Yet Recruiting | — | — | — |
NCT07281209CT.gov A Study of SHR-A1811 Combined With Adebelimumab as Neoadjuvant Therapy for Resectable HER2-Altered Non-Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT07229729CT.gov A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT07173244CT.gov A Real-world Study of Adebrelimab-based Combination Regimens in the Treatment of Advanced Solid Tumors | — | Not Yet Recruiting | — | — | — |
NCT07031154CT.gov A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT07035392CT.gov Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC | — | Not Yet Recruiting | — | — | — |
NCT06963502CT.gov A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors | — | Not Yet Recruiting | — | — | — |
NCT06844474CT.gov A Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC | — | Recruiting | — | — | — |
NCT06735508CT.gov MRNA Neoantigen Vaccine in Non-Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
Show 19 more trialsShow fewer
NCT06594874CT.gov A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors | — | Not Yet Recruiting | — | — | — |
NCT06434103CT.gov Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC | — | Withdrawn | — | — | — |
NCT06467617CT.gov Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC | — | Recruiting | — | — | — |
NCT06700421CT.gov Phase II Clinical Study of Adebrelimab Combined with Apatinib in the Treatment of Locally Advanced Non-small Cell Lung Cancer Patients with Radiation Pneumonitis | — | Active Not Recruiting | — | — | — |
NCT06512051CT.gov A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06480136CT.gov SHR-A1921 Combined With Adebrelimab in the Treatment of Advanced NSCLC Who Failed the Previous Standard First-line Treatment | — | Not Yet Recruiting | — | — | — |
NCT06424899CT.gov A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC | — | Recruiting | — | — | — |
NCT06299371CT.gov Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations | — | Not Yet Recruiting | — | — | — |
NCT06335355CT.gov A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients | — | Not Yet Recruiting | — | — | — |
NCT06182800CT.gov Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy | — | Unknown | — | — | — |
NCT05932264CT.gov Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT05738317CT.gov Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel in Non-squamous NSCLC After First-line Treatment | — | Unknown | — | — | — |
NCT05565417CT.gov Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | — | Active Not Recruiting | — | — | — |
NCT05416775CT.gov Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT03976856CT.gov Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib | — | Unknown | — | — | — |
NCT02976116CT.gov A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT02691299CT.gov A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT02590965CT.gov A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT06685653CT.gov Personalized Neoantigen MRNA Vaccine Combined with Adebrelimab in Non-Small Cell Lung Cancer Patients | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Adebrelimab (this asset) | Peking University Cancer Hospital & Institute | P3 | BB · 66 |
| Necitumumab | Jonsson Comprehensive Cancer Center | P3 | BBB |
| Glumetinib | Shanghai JMT-Bio Inc. | P3 | BBB |
| Veliparib | AbbVie | P3 | BBB |
| d-0316 | Betta Pharmaceuticals Co., Ltd. | P2/3 | BBB |
| Icotinib | The First Affiliated Hospital of Guangzhou Medical University | P4 | BBB |
| Zoledronate | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | P4 | BBB |
| Onartuzumab | Hoffmann-La Roche | P3 | BBB |
| Avitinib | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | P3 | BBB |
+42 more in the Non-Small Cell Lung Carcinoma cohort
Other indications for Adebrelimab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colorectal Cancer | — | P4 | BB · 67 |
| Small Cell Lung Carcinoma | — | P3 | BB · 64 |
| Hepatocellular Carcinoma | — | P3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Adebrelimab in Non-Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/adebrelimab-non-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →